Literature DB >> 32933804

The prognostic value of sarcopenia combined with hepatolithiasis in intrahepatic cholangiocarcinoma patients after surgery: A prospective cohort study.

Liming Deng1, Yi Wang2, Jungang Zhao1, Yifan Tong1, Sina Zhang3, Chen Jin2, Kaiyu Chen1, Wenming Bao1, Zhengping Yu4, Gang Chen5.   

Abstract

INTRODUCTION: Intrahepatic Cholangiocarcinoma (ICC) is the second most common primary liver cancer with dismal survival rates. This study aimed to explore the prognostic value of sarcopenia combine with hepatolithiasis in surgically treated ICC patients and develop a prognostic nomogram to help make clinical decisions.
MATERIALS AND METHODS: A prospective cohort study was conducted including patients who underwent hepatectomy for ICC between August 2012 and October 2019. The association between the sarcopenia combined with hepatolithiasis and survival, including overall survival (OS) and recurrence-free survival (RFS) was investigated using the Kaplan-Meier (K-M) method. Univariable and multivariable Cox regression analysis was performed to determine the independent prognostic factors and a nomogram establishment was undertaken based on the multivariable analysis.
RESULTS: A total of 121 ICC patients were included in the study. K-M analysis revealed that ICC patients with sarcopenia and hepatolithiasis have worse OS and RFS than those without sarcopenias and/or hepatolithiasis (p < 0.01). Multivariable analysis showed that age, serum CEA, hepatolithiasis, sarcopenia and diabetes were independent prognostic factors for OS(p < 0.05). Finally, a nomogram with good performance in survival prediction was established (C-index was 0.721; the area under the curve of OS was 0.837). The stratified analysis based on the nomogram disclosed that the median OS was 11.9 months in high-risk patients and 51.2 months in low-risk patients (p < 0.001).
CONCLUSIONS: ICC patients with sarcopenia and hepatolithiasis have worse OS and RFS. The nomogram we developed is a practical tool that can provide a more individualized risk assessment for surgically treated ICC patients.
Copyright © 2020 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Hepatolithiasis; Intrahepatic cholangiocarcinoma; Nomogram; Prognosis; Sarcopenia

Year:  2020        PMID: 32933804     DOI: 10.1016/j.ejso.2020.09.002

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  4 in total

Review 1.  Clinical Impact of Sarcopenia on Cholangiocarcinoma.

Authors:  Suk-Pyo Shin; Dong-Hee Koh
Journal:  Life (Basel)       Date:  2022-05-30

2.  Sarcopenia predicts an adverse prognosis in patients with combined hepatocellular carcinoma and cholangiocarcinoma after surgery.

Authors:  Gui-Min Hou; Chuang Jiang; Jin-Peng Du; Ke-Fei Yuan
Journal:  Cancer Med       Date:  2021-12-05       Impact factor: 4.452

3.  A Novel Clinical-Radiomics Model Based on Sarcopenia and Radiomics for Predicting the Prognosis of Intrahepatic Cholangiocarcinoma After Radical Hepatectomy.

Authors:  Liming Deng; Bo Chen; Chenyi Zhan; Haitao Yu; Jiuyi Zheng; Wenming Bao; Tuo Deng; Chongming Zheng; Lijun Wu; Yunjun Yang; Zhengping Yu; Yi Wang; Gang Chen
Journal:  Front Oncol       Date:  2021-11-19       Impact factor: 6.244

4.  The prognostic value of sarcopenia combined with preoperative fibrinogen-albumin ratio in patients with intrahepatic cholangiocarcinoma after surgery: A multicenter, prospective study.

Authors:  Haitao Yu; Mingxun Wang; Yi Wang; Jinhuan Yang; Liming Deng; Wenming Bao; Bangjie He; Zixia Lin; Ziyan Chen; Kaiyu Chen; Baofu Zhang; Fangting Liu; Zhengping Yu; Longyun Ye; Bin Jin; Gang Chen
Journal:  Cancer Med       Date:  2021-06-08       Impact factor: 4.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.